Minneapolis Heart Institute
Make an Appointment

Valve Center

The Center for Valve and Structural Heart Disease

The Center for Valve and Structural Heart Disease at Minneapolis Heart Institute® at Abbott Northwestern Hospital is world renowned for clinical and innovative expertise. The full spectrum of state-of-the-art diagnostic testing is available. A multidisciplinary approach enables the delivery of the most innovative transcatheter and surgical therapies for treating valve and structural heart disease, including investigational approaches that are provided at only a few centers in the world.

The Center serves as a training site for multiple transcatheter and surgical therapies, and regularly teaches these approaches through live case demonstrations and high-quality didactics. In partnership with the Minneapolis Heart Institute Foundation, patients can participate in major clinical trials of valvular and structural heart disease. Current and prior studies include: Tendyne transcatheter mitral valve replacement Global Early Feasibility Study, Medtronic Intrepid transcatheter mitral valve replacement Global Early Feasibility Study, PARTNER 1, PARTNER 2, S3i CAP, SURTAVI, COAPT, REPRISE III, REPRISE III CAP, Myocor, PORTICO, EVEREST, and REALISM. A selected bibliography with highlights of this research is shown below.

In April 2015, the first transcatheter mitral valve replacement in the U.S. was performed at Minneapolis Heart Institute® and it continues to have the highest volume, in the world, of patients for this novel procedure.

Clinical practice

Our physicians, surgeons, and care providers see patients in a dedicated clinic, where a multidisciplinary, heart-team approach is highly valued. These subspecialists also participate in a weekly conference, where patient care is reviewed and discussed for consensus in diagnostic and treatment plans, and for coordination of services.
State-of-the-art therapies available (selected list):

  • Transcatheter mitral valve repair (MitraClip)
  • Transcatheter mitral valve replacement for native mitral regurgitation
  • Valve-in-valve therapy for prosthetic valve degeneration
  • Minimally-invasive mitral valve surgery (e.g., port access)
  • Mini-sternotomy aortic valve surgery
  • Paravalvular prosthetic leak repair
  • Transcatheter tricuspid valve repair
  • Balloon mitral valvuloplasty
  • Balloon aortic valvuloplasty
  • Alcohol septal ablation
  • Ventricular and aortic pseudoaneurysm transcatheter repair
  • Transcatheter closure of patent foramen ovale (PFO), atrial septal defect, and ventricular septal defect

Staff and Personnel

Paul Sorajja, MD
Director, Center for Valve and Structural Heart Disease

Wesley A. Pedersen, MD
Director, Transcatheter Valve Therapies

Mario Goessl, MD PhD
Director, Transcatheter Research and Education
Program Director, Advanced Fellowship in Structural Heart Disease Interventions

Interventional Cardiology
Mario Goessl MD, PhD
Michael Mooney, MD
Wesley Pedersen, MD
Anil Poulose, MD
Paul Sorajja, MD

Cardiac Surgery
R. Saeid Farivar, MD PhD, Chairman
Judah Askew, MD
Frazier Eales, MD
Thomas Flavin, MD
Vibhu Kshettry, MD
Karol Mudy, MD

Advanced Cardiovascular Imaging
Richard Bae, MD
Kevin Harris, MD
Desmond Jay, MD
John Lesser, MD
David Lin, MD
Marc Newell, MD

Advanced Practice Providers
Marcus Burns, DNP
Lynelle Schneider, PA

Care Coordinator
Susan Jagger, RN

Research Coordinators
Kate Jappe, RN
Pamela Morley, RN
Karen Meyer, RN
Sara Olson, RN
Lisa Tindell, RN

Administrative Assistant
Madeline Squires
Ron Beese

Presentations on valvular heart disease

The heart valve center of excellence

Interview with Paul Sorajja, MD on mitral centers

The Hybrid Room

Patient story

Living again, thanks to new valve repair option

Selected Bibliography

  1. Sorajja P, Gossl M. Where are the boundaries for transcatheter valve therapy? JACC Cardiovasc Interv 2016;9:1372-3.
  2. Sorajja P, Pedersen WA, Baee R, et al. First experience with percutaneous mitral valve plication as primary therapy for symptomatic obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2016;67:2811-8.
  3. Sorajja P, Mack M, Vemulapalli S, et al. Initial experience with commercial transcatheter mitral valve repair in the United States. J Am Coll Cardiol 2016;67:1129-40.
  4. Latib A, Pedersen W, Maisano F, et al. Initial findings using the V8 hourglass-shaped valvuloplasty balloon for postdilation treating paravalvular leaks associated with transcatheter self-expanding aortic valve prosthesis. Catheter Cardiovasc Interv 2016;87:1306-13.
  5. Sorajja P. Transcatheter aortic valve replacement: a transformative technology. Prog Cardiovasc Dis 2014;56:563-4.
  6. Pedersen WA, Mooney MR, Ungs D, Pedersen C, Sorajja P, Poulose AK, Stark RP, Murad B, Garberich RF, Goldenberg E, Schwartz RS. Improvement in aortic valve area using a new hour glass shaped valvuloplasty balloon compared with standard cylindrical balloons in severe aortic stenosis patients. Minerva Cardioangiol 2014;62:243-9.
  7. Sorajja P, Pedersen WA. Next-generation transcatheter aortic valve replacement: evolution of a revolution. J Am Coll Cardiol 2014;64:1349-51.
  8. Lesser JR, Han BK, Newell M, Schwartz RS, Pedersen W, Sorajja P. Use of cardiac CT angiography to assist in the diagnosis and treatment of aortic prosthetic paravalvular leak: a practical guide. J Cardiovasc Comput Tomogr 2015;9:159-64.
  9. Sorajja P, Lesser, Bae R, Pedersen WA. Percutaneous repair of paravalvular prosthetic regurgitation: patient selection, techniques, and outcomes. Heart 2015;101:665-73.
  10. Nemoto N, Lesser JR, Pedersen WR, Sorajja P, Spinner E, Garberich RF, Vock DM, Schwartz RS. Pathogenic structural heart changes in early tricuspid regurgitation. J Thorac Cardiovasc Surg 2015;150:323-30.
  11. Kanda BS, Jay D, Farivar RS, Sorajja P. Leaflet-to-annuloplasty ring clipping for severe mitral regurgitation. JACC Cardiovasc Interv 2016;9:e63-4.
  12. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, O’Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt TM 3rd, Thomas JD. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2014 Mar 3 [Epub ahead of print]
  13. Eleid MF, Sorajja P, Michelena HI, Malouf JF, Scott CG, Pellikka PA. Flow-gradient patterns in severe aortic stenosis with preserved ejection fraction: clinical characteristics and predictors of survival. Circulation 2013;128:1781-9.
  14. Sorajja P, Ommen SR, Dearani JD, Holmes DR Jr., Rihal CS, Gersh BJ, Nishimura RA. Survival after septal alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation 2012;126:2374-80.

Referring patients

Scheduling of patients and transfer of medical records:
Call 612-863-VALV (8258) for a direct line to our dedicated care coordinators, who will be able to expedite the scheduling of patients and transfer of medical records.

Talk to one of our cardiologists:
Medical providers can call 612-863-8800 for Cardiology Curbside.

Patient image transfer

Thank you for entrusting us in the ongoing care of your patient. Please contact 612-863-8258, Monday to Friday from 8:00 a.m. – 4:30 p.m., for the password to transfer images. Login to transfer patient images.

Patient information

If you are a patient or have a family member with valve disease, learn more about types of valve diseases, symptoms and treatments.